blinatumomab治疗后的细胞因子释放综合征
Cytokine Release Syndrome Following Blinatumomab Therapy.
作者信息
Ojemolon Pius E, Kalidindi Sunaina, Ahlborn Taylor A, Aihie Osaigbokan P, Awoyomi Moyosoluwa I
机构信息
Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, USA.
Internal Medicine, Midwestern University Chicago College of Osteopathic Medicine, Chicago, USA.
出版信息
Cureus. 2022 Jan 25;14(1):e21583. doi: 10.7759/cureus.21583. eCollection 2022 Jan.
Abstract
New therapeutic solutions have emerged in the last few decades with the growth and expansion of the field of cancer research. Amongst these new agents, immunotherapy has been prominent, particularly regarding the treatment of hematologic malignancies. One of the most worrisome complications of immunotherapy is cytokine release syndrome (CRS), which represents a supraphysiologic response resulting in excessive release of cytokines and a wide range of systemic manifestations. In this case report, we present a case of cytokine release syndrome following blinatumomab therapy despite premedication with dexamethasone.
摘要
在过去几十年里，随着癌症研究领域的发展和扩展，出现了新的治疗方案。在这些新药物中，免疫疗法尤为突出，特别是在血液系统恶性肿瘤的治疗方面。免疫疗法最令人担忧的并发症之一是细胞因子释放综合征（CRS），它代表一种超生理反应，导致细胞因子过度释放和一系列全身表现。在本病例报告中，我们呈现了一例尽管在使用贝林妥欧单抗治疗前使用了地塞米松预处理，但仍发生细胞因子释放综合征的病例。
相似文献
1
Cytokine Release Syndrome Following Blinatumomab Therapy.blinatumomab治疗后的细胞因子释放综合征
Cureus. 2022 Jan 25;14(1):e21583. doi: 10.7759/cureus.21583. eCollection 2022 Jan.
2
Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.在一名患有4级细胞因子释放综合征的复发/难治性急性淋巴细胞白血病患者中成功重新使用博纳吐单抗。
J Oncol Pharm Pract. 2018 Jan;24(1):67-73. doi: 10.1177/1078155216676633. Epub 2016 Oct 31.
3
A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.Blinatumomab 治疗急性淋巴细胞白血病的系统评价：用新方法解决老问题。
Ann Pharmacother. 2021 Oct;55(10):1236-1253. doi: 10.1177/1060028020988411. Epub 2021 Jan 13.
4
Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.新型急性淋巴细胞白血病治疗相关细胞因子释放综合征：发病机制、预防和治疗。
Curr Oncol Rep. 2019 Jan 21;21(1):4. doi: 10.1007/s11912-019-0753-y.
5
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.blinatumomab 治疗后细胞因子释放综合征与异常巨噬细胞活化有关，并通过细胞因子导向治疗得到改善。
Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15.
6
A review of blinatumomab, a novel immunotherapy.新型免疫疗法——博纳吐单抗综述
J Oncol Pharm Pract. 2016 Aug;22(4):639-45. doi: 10.1177/1078155215618770. Epub 2015 Nov 24.
7
Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.病例报告：嵌合抗原受体 T 细胞治疗后急性淋巴细胞白血病患者出现局部细胞因子释放综合征：一种可能的模型、文献回顾与展望。
Front Immunol. 2021 Jul 19;12:707191. doi: 10.3389/fimmu.2021.707191. eCollection 2021.
8
Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.细胞因子基因多态性与blinatumomab 治疗 B 细胞急性淋巴细胞白血病的反应相关。
Eur J Haematol. 2021 Jun;106(6):851-858. doi: 10.1111/ejh.13622. Epub 2021 Mar 24.
9
Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.博纳吐单抗：填补成人复发/难治性B细胞急性淋巴细胞白血病治疗空白
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S2-5. doi: 10.1016/j.clml.2016.02.001.
10
Management of cytokine release syndrome related to CAR-T cell therapy.细胞因子释放综合征相关的 CAR-T 细胞治疗的管理。
Front Med. 2019 Oct;13(5):610-617. doi: 10.1007/s11684-019-0714-8. Epub 2019 Sep 28.
引用本文的文献
1
Blinatumomab in pediatric B-acute lymphoblastic leukemia.博纳吐单抗治疗儿童B细胞急性淋巴细胞白血病
Front Immunol. 2025 Jul 23;16:1611701. doi: 10.3389/fimmu.2025.1611701. eCollection 2025.
2
Insights from the bottom-up development of LGR5-targeting immunotherapeutics.靶向LGR5的免疫疗法自下而上开发的见解。
Immunother Adv. 2025 Apr 25;5(1):ltaf017. doi: 10.1093/immadv/ltaf017. eCollection 2025.
3
A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review.一例因戈利妥单抗导致的持续性细胞因子释放综合征病例报告及文献综述
Clin Pharmacol. 2025 Apr 29;17:79-83. doi: 10.2147/CPAA.S515122. eCollection 2025.
4
The critical impacts of cytokine storms in respiratory disorders.细胞因子风暴在呼吸系统疾病中的关键影响。
Heliyon. 2024 Apr 17;10(9):e29769. doi: 10.1016/j.heliyon.2024.e29769. eCollection 2024 May 15.
5
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.髓系和树突状细胞增强了人源化 BRGSF-HIS 临床前模型中治疗诱导的细胞因子释放综合征特征。
Front Immunol. 2024 Feb 7;15:1357716. doi: 10.3389/fimmu.2024.1357716. eCollection 2024.
6
[Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].[博纳吐单抗治疗复发/难治性急性淋巴细胞白血病的临床疗效及不良反应分析]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):516-519. doi: 10.3760/cma.j.issn.0253-2727.2023.06.015.
7
Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.细胞因子释放综合征与癌症免疫疗法——历史挑战与光明前景。
Front Immunol. 2023 May 25;14:1190379. doi: 10.3389/fimmu.2023.1190379. eCollection 2023.
8
Advances in antibody-based therapy in oncology.肿瘤学中基于抗体疗法的进展。
Nat Cancer. 2023 Feb;4(2):165-180. doi: 10.1038/s43018-023-00516-z. Epub 2023 Feb 20.
本文引用的文献
1
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.成人复发/难治性B细胞前体急性淋巴细胞白血病患者在使用blinatumomab之前进行肿瘤减灭的真实世界多中心经验。
Front Oncol. 2022 Jan 6;11:804714. doi: 10.3389/fonc.2021.804714. eCollection 2021.
2
[Bispecific antibodies in onco-hematology: Applications and perspectives].[双特异性抗体在肿瘤血液学中的应用与前景]
Bull Cancer. 2021 Oct;108(10S):S195-S204. doi: 10.1016/j.bulcan.2021.10.002.
3
Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?预防性治疗是嵌合抗原T细胞疗法相关细胞因子释放综合征的唯一出路吗？
Cureus. 2021 Sep 4;13(9):e17709. doi: 10.7759/cureus.17709. eCollection 2021 Sep.
4
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.接受 axi-cel 治疗的大 B 细胞淋巴瘤患者中预防性使用皮质类固醇。
Br J Haematol. 2021 Aug;194(4):690-700. doi: 10.1111/bjh.17527. Epub 2021 Jul 22.
5
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.嵌合抗原受体 T 细胞治疗 B 细胞非霍奇金淋巴瘤中细胞因子释放综合征模型。
Signal Transduct Target Ther. 2020 Jul 29;5(1):134. doi: 10.1038/s41392-020-00256-x.
6
Cellular therapy: Immune-related complications.细胞治疗：免疫相关并发症。
Immunol Rev. 2019 Jul;290(1):114-126. doi: 10.1111/imr.12768.
7
Cytokine release syndrome.细胞因子释放综合征。
J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9.
8
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.嵌合抗原受体 T 细胞引起的细胞因子释放综合征是由巨噬细胞介导的，并可通过白细胞介素-1 阻断来减轻。
Nat Med. 2018 Jun;24(6):731-738. doi: 10.1038/s41591-018-0041-7. Epub 2018 May 28.
9
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.综述：细胞因子风暴综合征：迈向精准医学时代
Arthritis Rheumatol. 2017 Jun;69(6):1135-1143. doi: 10.1002/art.40071.
10
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.急性淋巴细胞白血病新型疗法引发的细胞因子释放综合征
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):567-572. doi: 10.1182/asheducation-2016.1.567.
Zotero 插件